Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?

Citation
Coleman RL, Gray AM, Broedl Md UC, et al. Diabetes Obes Metab 2020;22:1151–6.